Importantly, the RAAS is a critical component of the electrical remodeling of the failing heart, and the RAAS blockade lowers the risk of SCD, with the ARBs representing a robust tool to enhance overall survival and possibly curtail the risk of SCD provided that adequate drug doses are used to reach optimal AT1-receptor blockade [162]. The gene discussed is AGTR1; the disease is Schnyder corneal dystrophy.